Jafron Biomedical Co.,Ltd. (300529.SZ)
CNY 30.04
(-0.07%)
CNY 30.04
(-0.07%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 543.81 Million CNY | -47.17% |
| 2022 | 1.02 Billion CNY | -27.4% |
| 2021 | 1.41 Billion CNY | 34.48% |
| 2020 | 1.05 Billion CNY | 54.98% |
| 2019 | 680.32 Million CNY | 42.83% |
| 2018 | 476.3 Million CNY | 43.59% |
| 2017 | 331.7 Million CNY | 41.9% |
| 2016 | 233.76 Million CNY | 0.75% |
| 2015 | 232.04 Million CNY | 33.32% |
| 2014 | 174.04 Million CNY | 19.95% |
| 2013 | 145.09 Million CNY | 28.49% |
| 2012 | 112.92 Million CNY | 30.95% |
| 2011 | 86.24 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 321.59 Million CNY | 1020.94% |
| 2024 Q3 | 307.37 Million CNY | -1.74% |
| 2024 Q2 | 312.81 Million CNY | -2.73% |
| 2023 FY | 543.81 Million CNY | -47.17% |
| 2023 Q4 | 28.68 Million CNY | -83.66% |
| 2023 Q3 | 175.6 Million CNY | 75.0% |
| 2023 Q1 | 239.17 Million CNY | 2941.7% |
| 2023 Q2 | 100.34 Million CNY | -58.05% |
| 2022 Q3 | 141.53 Million CNY | -70.89% |
| 2022 FY | 1.02 Billion CNY | -27.4% |
| 2022 Q2 | 486.28 Million CNY | 23.5% |
| 2022 Q1 | 393.76 Million CNY | -2.52% |
| 2022 Q4 | 7.86 Million CNY | -94.44% |
| 2021 FY | 1.41 Billion CNY | 34.48% |
| 2021 Q1 | 334.71 Million CNY | 10.48% |
| 2021 Q4 | 403.95 Million CNY | 42.94% |
| 2021 Q3 | 282.6 Million CNY | -28.75% |
| 2021 Q2 | 396.65 Million CNY | 18.5% |
| 2020 Q4 | 302.96 Million CNY | 36.91% |
| 2020 Q3 | 221.29 Million CNY | -26.89% |
| 2020 FY | 1.05 Billion CNY | 54.98% |
| 2020 Q1 | 227.38 Million CNY | 23.69% |
| 2020 Q2 | 302.69 Million CNY | 33.12% |
| 2019 Q1 | 154.41 Million CNY | 23.25% |
| 2019 Q2 | 207.56 Million CNY | 34.42% |
| 2019 Q4 | 183.83 Million CNY | 36.66% |
| 2019 FY | 680.32 Million CNY | 42.83% |
| 2019 Q3 | 134.51 Million CNY | -35.19% |
| 2018 Q4 | 125.28 Million CNY | 8.22% |
| 2018 Q2 | 127.89 Million CNY | 19.13% |
| 2018 Q1 | 107.35 Million CNY | 7.44% |
| 2018 FY | 476.3 Million CNY | 43.59% |
| 2018 Q3 | 115.77 Million CNY | -9.48% |
| 2017 Q4 | 99.92 Million CNY | 52.94% |
| 2017 Q1 | 69.09 Million CNY | -5.86% |
| 2017 FY | 331.7 Million CNY | 41.9% |
| 2017 Q2 | 97.35 Million CNY | 40.89% |
| 2017 Q3 | 65.33 Million CNY | -32.89% |
| 2016 Q2 | 61.08 Million CNY | 12.1% |
| 2016 FY | 233.76 Million CNY | 0.75% |
| 2016 Q4 | 73.4 Million CNY | 63.9% |
| 2016 Q3 | 44.78 Million CNY | -26.69% |
| 2016 Q1 | 54.49 Million CNY | -25.63% |
| 2015 FY | 232.04 Million CNY | 33.32% |
| 2015 Q4 | 73.27 Million CNY | 44.81% |
| 2015 Q3 | 50.6 Million CNY | -12.19% |
| 2015 Q2 | 57.62 Million CNY | 14.0% |
| 2015 Q1 | 50.54 Million CNY | 0.0% |
| 2014 FY | 174.04 Million CNY | 19.95% |
| 2013 FY | 145.09 Million CNY | 28.49% |
| 2012 FY | 112.92 Million CNY | 30.95% |
| 2011 FY | 86.24 Million CNY | 0.0% |